Multiple myeloma is a rare type of cancer that develops in plasma cells. A cure for Multiple Myeloma currently doesn’t exist. However, significant research is making progressive leaps toward a treatment that eliminates cancer entirely.
As per Delveinsight's estimate, Market Size of CAR T-Cell Therapy for Multiple Myeloma in the 6MM is expected to be USD 3,766.4 Million in 2030.
Owing to the launch of upcoming therapies, market size shall increase during the forecast period (2020-2030). The Emerging Therapies like bb2121, JNJ 68284528, Descartes-08, JCARH125 PBCAR269A, P-BCMA-101 CAR-T cells and MLM-CAR44.1 T-cells can entirely change the Multiple Myeloma treatment landscape.
Some of the key companies in the CAR T-Cell Therapy for Multiple Myeloma Market include Bluebird bio/Celgene, Janssen Research & Development, Poseida Therapeutics, MolMed S.p.A., Celgene Corporation, Cartesian Therapeutics, CARsgen Therapeutics, Precision BioSciences, and many others.
For more details visit: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-multiple-myeloma-market